Latest Posts
About This Stock
More About This Stock
Read
Read
Read
Sarepta Seen As 'Bargain' For Potential Big Pharma Buyer
Article By:
The Fly
Thursday, June 8, 2017 3:48 PM EDT
While approval for Sarepta Therapeutic's Exondys 51 in the U.S. was controversial, Oppenheimer analyst Hartaj Singh said it has resulted in a "high level" of short interest and the company would be a "bargain" if it is acquired.
Regeneus Hits The Fast Track With Major Japanese Partnership
Article By:
The Life Sciences Report
Thursday, February 9, 2017 1:57 PM EDT
Regeneus, an Australian company, has entered into an collaboration with a major Japanese firm to manufacture its stem cell therapy Progenza, a move that may accelerate approval and that has a pair of analysts optimistic about the company's future.
Bill Ackman Cut His Valeant Stake; Will Bloodbath Ensue?
Article By:
Shock Exchange
Wednesday, December 14, 2016 2:40 PM EDT
Pershing Square's Bill Ackman cut his VRX stake. Asset sales have not occurred and a Fed rate hike could dampen future sales. VRX's intrinsic value is less than $1. Bulls could follow the "smart money" and sell VRX en masse. Will a bloodbath ensue?